8/1/17 Public update of BioSculpture Technology, Inc. Business Plan and Corporate Capsule for Investors

1. August 1, 2017
Investor Presentation
Highlights
© 2017 BioSculpture Technology, Inc. All rights reserved.

2. REGULATION A+ Allows companies to raise up to $50M from retail investors in an SEC registered offering.
REGULATION D - RULE 506(c) Allows companies to raise capital from accredited investors only and market the offering.
BIOCULPTURE TECHNOLOGY, INC. (“BIOCULPTURE”) HAS LAUNCHED A TEST THE WATERS CAMPAIGN FOR
A REGULATION A+ OFFERING. WE ARE NOW ACCEPTING NON-BINDING INDICATIONS OF INTEREST
(RESERVATIONS)
NO MONEY OR OTHER CONSIDERATION IS BEING SOLICITED FOR OUR REGULATION A+ OFFERING AT THIS
TIME AND IF SENT IN TO BIOCULPTURE WILL NOT BE ACCEPTED. NO OFFER TO BUY SECURITIES IN A
REGULATION A+ OFFERING OF BIOCULPTURE CAN BE ACCEPTED AND NO PART OF THE PURCHASE PRICE
CAN BE RECEIVED UNTIL BIOCULPTURE’S OFFERING STATEMENT IS QUALIFIED. ANY SUCH OFFER TO BUY
SECURITIES MAY BE WITHDRAWN OR REVOKED, WITHOUT OBLIGATION OR COMMITMENT OF ANY KIND,
AT ANY TIME BEFORE NOTICE OF ITS ACCEPTANCE GIVEN AFTER THE QUALIFICATION DATE. ANY
INDICATIONS OF INTEREST IN BIOCULPTURE’S OFFERING INVOLVES NO OBLIGATION OR COMMITMENT OF
ANY KIND.
PRIVATE PLACEMENT RULE 506(C) OFFERING
AN INVESTMENT IN BIOCULPTURE THROUGH PRIVATE PLACEMENT IN OUR 506(C) OFFERING MAY ONLY BE
MADE BY ACCREDITED INVESTORS THROUGH THIRD PARTY VERIFICATION AND WRITTEN CONFIRMATION
FROM ONE OF THE FOLLOWING: A REGISTERED BROKER DEALER, A REGISTERED INVESTMENT ADVISOR, A
LICENSED ATTORNEY OR A CPA, THAT THEY HAVE VERIFIED ACCREDITED INVESTOR STATUS IN THE LAST
THREE MONTHS, WITH AND FOLLOWING REVIEW OF A CONFIDENTIAL PRIVATE PLACEMENT
MEMORANDUM. THIS PACKAGE OF INFORMATION IS NOT MEANT TO REPLACE OR SUPPLEMENT THE
CONFIDENTIAL PRIVATE PLACEMENT MEMORANDUM.
Disclaimer 1

3. Forward Looking Statements
Any forecasts and pro forma financial information contained herein
or which are part of the Company’s business plan, are for illustrative
purposes only and are based upon assumptions made by Management
regarding hypothetical future events.
Management believes these assumptions are reasonable and
furthermore to the best of its knowledge that all the facts contained
herein are true and there are no material errors or omissions.
There is no assurance that actual events will correspond with the
assumptions or that factors beyond the control of the Company will not
affect the assumptions and adversely affect the illustrative value and
conclusions of any forecasts.
2

4. BioSculpture Technology, Inc. Company Profile
Company Profile Key Financials
 BioSculpture Technology, Inc. (“BST”) is a
commercial-stage medical device manufacturer
developing a patented minimally invasive method
and device for the endoscopic removal of visceral
or “belly” fat as a new treatment of obesity,
metabolic syndrome and type 2 diabetes mellitus.
 Large IP portfolio: 3 patents on method and device
with numerous more U.S. pending.
 Proven concept: first generation of successful
technology was licensed to UAM, NuMed, Byron
Medical/Mentor/Ethicon generated $150 MM in
revenues annually.
 Small & medium volume
liposuction
Airbrush®
Liposculptor III
Airbrush®
Liposculptor IIE EVL®
 Medium & Large volume
liposuction
 Precision liposuction
 Endoscopic Visceral
Lipectomy
FME 5/31/17 $1,000‘s
2017 2018 2019 2020 2021
SALES $0 $3,017 $16,222 $24,181 $33,880
EBITDA ($1,942) ($270) $1,844 $3,042 $4,547
NET INCOME($1,978,936) ($318,144) $1,796,303 $2,994,106 $3,042,199
3

5. Experienced Management Team
Name Title Background
Robert L.
Cucin, MD,
FACS
Founder,
President
& CEO
 Inventor of both PAL and TCAL; board-certified plastic and reconstructive
and general surgeon.
 BA (Cornell), M.D. (Cornell), JD (Fordham), MBA (Columbia).
 18 patents, 5 books, 24 articles, and one ballet score.
 Founded and Directs Rocin Laboratories, Inc., a biomedical Research and
Development company which licensed his first liposuction patent non-
exclusively to NuMed, UAM, Byron Medical, Mentor, and Ethicon.
 Founded and directed Plastic Surgical Research to support IACUC studies
and clinical IRB’s carried out at academic centers.
 Founded and Directed the American Institute of Plastic Surgery (NYC).
 Licensed Securities professional: Series 4, Series 7, Series 24, Series 27, Series
63, Series 65, Series 79, Series 86/87, Series 99.
Deborah
Salerno
CFO  Currently holds 7, 24, 63 and 79 Securities licenses.
 Managing Director of DAS Consulting LLC.
 She been active in PIPEs and provides expertise in the alternative Public
Offerings market as well as traditional banking.
Simon
Taylor, Esq.
Corporate
Counsel
 Columbia University and Harvard Law School graduate with broad
experience with biotechnology and medical devices, technology and IP start-
ups and ramp-ups, and venture financing.
 Former Partner of Snow Becker Krauss.
4

6. Advisory Board
Name Title Background
Peter
Ciriscioli,
BS MS PhD
Engineering
Consultant
 BS and MS in Materials Science and Engineering from the University of
California and a PhD in Mechanical Engineering from Stanford University.
 Director of JLTV Programs for BAE Systems, Program Manager of the
Engineering Mechanics Laboratory at General Electric Corporate Research.
 Director of Research for the Fiberite Corporation where he led 30 engineers
and scientists in U.S., U.K. and Europe and was responsible for the strategy
and implementation of new technologies and products.
 4 patents, two books, and more than 20 published journal articles.
Brigadier
General
Richard B.
Yules, MD
Medical
Advisor
 Yale B.S. and M.D, Board-certified otolaryngologist, having completed
surgical residences at Stanford and Harvard universities, where he still
maintains a faculty position.
 Air National Guard assistant to the deputy assistant secretary of defense
Pentagon, Washington, D.C.
 Published over fifty manuscripts and chapters, including four books.
 Sits on the Board of several public and private companies.
Thomas J.
Perkowski,
Esq.
Patent
Prosecution
 B.S. E.E Clarkson College of Technology
 J.D. Franklin Pierce Law Center of Concord, New Hampshire.
 Former Associate of Hopgood, Calimafde, Judlow and Mondolino (NYC)
 Successfully prosecuted over 650 patents
5

7. Large Growth Opportunity
Liposuction
Large Addressable Market
 2/3 of the U.S. population is overweight; 1/3 is frankly obese; forecast to grow to 43% in
few years.
 2.1B obese people Worldwide forecast to grow to 50% of the world’s population by 20301
 Obesity related disease yearly expenditures exceed $2T worldwide.1
 Nearly $14B spent on cosmetic procedures in 2015, 5% increase from 20142.
 $668M spent on liposuction in 2015 (4.8%).
 $3,009 average surgeon’s fee / procedure in 2015.
 Traditional liposuction and all other devices are
technologically limited to small and medium
volume subcutaneous fat removal.
 Disruptive technology: BST’s Twin-Cannula
Assisted Liposuction (“TCAL”) allows
liposuction to become an operation of pounds
rather than inches.
Bariatric Treatment
 A safer and faster alternative to current
restrictive or bypass bariatric surgery.
 No cutting into the stomach, bowel or
rearranging alimentary plumbing.
 Less invasive with no foreign body to erode
esophagus or skin, or cause malabsorption
syndromes and diarrhea (no quality of life
compromise).
 Bariatric surgeries reached 220,000 in 2008.
 Bariatric surgery spending $1.5B in 2016.
1. McKinsey Global Institute report released 11/20/14.
2. American Society of Plastic Surgeons report released 3/9/16.
6

8. Bazzocchi, A Diano, D Battista G How Fat is Fat? Lancet 380:e1 (2012)
 Visceral fat removal  Subcutaneous fat removal
Different Fat Requires Different Treatments
Endoscopic Visceral Lipectomy with EVL® Liposuction with Airbrush® Liposculptor IIE
 Accumulation of subcutaneous and visceral types of fat has different consequences for
human body and EVL® and Airbrush® Liposculptor IIE provide viable and economic
solutions for effective removal of both types of fat
7

9. Product Overview
Airbrush®
Liposculptor III
Airbrush®
Liposculptor IIE EVL®
Application
Cosmetic & liposuction Cosmetic & liposuction Treatment & Visceral lipectomy
Obese patients, overweight patients
with elevated waist-to-hips ratios,
(~2B people, 43% of population)
$1,700 per procedure, 84% margin
Small and medium volume
liposuction (1/3 the population)
$ 100 per procedure, 80% margin
Medium and large volume
liposuction (1/3 population)
$100 per procedure, 80% margin
Insurance
No, out-of-pocket, discretionary
procedure
No, out-of-pocket, discretionary
procedure
Yes, reimbursed, indicated
procedure as well as still
discretionary (or proactive)
procedure
Purchaser
Dermatologists, plastic surgeons
and general surgeons performing
liposuction
Plastic surgeons, gynecologists &
general surgeons performing
liposuction
General and bariatric surgeons who
do endoscopic procedures
Market Size $500M device, up to $1B surgical fees can be targeted with single use
per-procedure consumables
$1.4B/yr. and expandable up to the
$2T/yr. obesity-related disease
expenditures
Patent & Method Protected Products
8

10.  Adjustable reciprocation stroke (1.3 -2”).
 Eliminates surgeon’s need to stroke the
cannula, saving labor and time while
improving consistency and control.
 No vibration since outer cannula is
stationary.
 Gentler on surgeon and patient as inner
cannula doesn’t traumatize patient since
it is ensheathed in stationary outer one
 Intellimotion® control with feedback
closed loop DSP control and magnetic
coupling safe guards.
× Only vibrates (1/4”).
× Surgeon must still manually reciprocate
the cannula to aspirate fat.
× Vibration annoying to surgeon and can
cause carpal tunnel syndrome and tennis
elbow.
× Patient sustains trauma from 10’s of
1,000’s of advancing cannula impacts.
× We also invented this technology but
developed and adopted labor saving
tube-within-a-tube designs.
Airbrush® Advantage
Single Cannula Power Assisted Liposuction Twin Cannula Assisted Liposuction
Vibrates externally
9

11. Competitive Positioning of Liposuction Products
Airbrush® II & IIE
(TCAL)
Airbrush® III
PAL (Power
Assisted
Liposuction)
UAL (Ultrasound
Assisted
Liposuction)
LAL (LASER
Assisted
Liposuction)
Stroke Power-assisted Power assisted Manual Manual Manual
Action Twin Cannula,
adjustable long Stroke
II: 2” eliminates
surgeon’s manual
stroke; electric
Single cannula, short
stroke: 3/8” option of
rotation; twin cannulas
possible; assists
surgeon’s manual
stroke, electric
Single cannula vibrates
(~1/8”) at 4KHz; gas
and electric
Single cannula vibrates
<1/10” at 40KHz to
melt fat
Fiber directs laser light
source to melt fat
Vibration Vibration minimized
by tube-within-tube
design both in front,
also in rear IIE
Vibration minimized
by stationary barb
Heavy vibration; tubing
moves with cannula,
repetitive stress injury
not common
No aspiration: must
remove fat manually
after strokes
No aspiration; must
remove fat manually
after strokes
Risk of Burns None None None Significant if surgeon
moves hot tip too
slowly
Significant if surgeon
moves hot tip too
slowly
Tissue
Trauma
Gentler twin-cannula
design minimizes
tissue trauma
Single cannula designs
minimize tissue trauma
and twin-cannula
version possible to
minimize it further.
Vibrating tip
traumatizes tissue
Hot tip causes cellular
injury
Hot tip causes cellular
injury
Curved
Cannulas
Possible, prototyped
and ready for roll out
Possible on twin
cannula version
Impossible Impossible Impossible
Price $50,000 $9,000 $14,000 $40,000 $60,000
10

12. Autoimmune diseases
Cancers
Strokes
Heart attacks
Angina
Low energy
Hunger
Kidney failure
Blindness
Obesity Morbidity: Visceral Fat is a Noxious Cytokine Factory
The Marker for Visceral Fat is a Bulging
Waistline
An Elevated Waist to Hips Circumference
Ratio Signals Metabolic Syndrome (WHR)
• Visceral fat is responsible for all the morbidities associated with obesity.

13. EVL® Device Enables a Safer Bariatric Surgical Alternative
Existing Surgical Options
 Surgical risks of cutting into the stomach or
bowel, rearranging the body’s alimentary
plumbing or leaving behind a foreign body.
 Adverse nutritional consequences and
untoward sequelae compromise life
outcomes.
 Patients eventually encounter a weight loss
plateau and gain back lost weight.
 Patients require indefinite surgical follow-
up and regular lab testing.
 Invasive and expensive.
Endoscopic Visceral Lipectomy (EVL)
 Provides the benefits of existing options
with fewer possible surgical complications
and with no lifestyle compromises.
 No cutting into the stomach, bowel or
rearranging the alimentary plumbing, or
leaving behind a foreign body.
 No adverse nutritional effects or untoward
sequelae
 Results expected to be permanent
 Procedure may be repeated until ideal
weight is obtained.
 Minimally invasive and cost effective.

14. EVL® Directly Removes The Noxious Cytokine Factory
https://youtu.be/5xC8pvNmMeI• If embedded video above fails to play, click on icon or link:
13

15. Projected Development Timeline
QUARTERS FROM COMPLETION OF FUNDING
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8
Airbrush® II Sell
inventory
Use up direct
materials for final
run
Sell last units
Airbrush® IIE Tweak Beta
Prototype
510(k) Start Production Commence
Sales
Get CE
Airbrush® III Tweak Beta
Prototype
510(k) Start
Production
Commence
Sales
Get CE
Airbrush®
Collectors
Tweak Beta
Prototypes
510(k) Start
Production
Commence
Sales
Get CE
EVL® Tweak Beta
Prototype
Add cautery
510 (K)
without
cautery
Start Production
Tweak Cautery
Commence
Sales Supplemental
510(k) with
cautery
Commence
Sales
Clinicals
abroad
Supplemental
or modified
510(k) for
additional
indication
Promote as
Lap-Band®
Alternative
Get CE
14

16. Sales and Marketing
 Management has extensive personal connection with major research hospitals and
surgery centers, respected doctors and Key Opinion Leaders (“KOL’s”).
 Placement with podium doctors
 Direct marketing to hospitals and doctor training.
 White papers and peer-reviewed articles from medical centers.
 Promotional budget set at 20% of sales.
 Direct trade “rifle barrel” advertising with and internet rich media.
 Cooperative advertising with promotional incentives to multiply the effect of
the advertising budget, establish our brand brand and create patient flow
(“pull”).
 Domestic: combination of salaried representatives in key cities (LA and NYC)
and independent representatives elsewhere fed leads from trade shows and
advertising.
 International: use of distributors.
 License and refer patients to branded treatment centers cross-selling bariatric
surgery, liposuction, and adipocyte-derived stem cell autografts.
EVL®
15

17. Key Financial Summary
 Prices: Airbrush® II: $50,000, Airbrush® IIE: $50,000, EVL® : $50,000, Airbrush® III: $9,000.
 Consumables: Airbrush® II, IIE and III: $100, EVL® liposuction pack: $300, visceral lipectomy pack: $1,700.
 Average product margin: 20%, 17%, and 83% respectively.
 Product Launch and sales begin in Q4 2018 (Oct. 2018).
 2018 unit sales: Airbrush® IIE: 21 domestic, 11 international; Airbrush® III: 25 domestic, 13 international;
EVL®: 6 domestic and 3 international.
 EVL® sold initially as an endoscopic subcutaneous lipoaspiration device only until additional indication of
visceral fat removal obtained, forecast for 2018.
 Buy/Try conversion ratio: 31%.
 International/Domestic unit sales: 50% (2016) growing to 100% (2021).
 Annual unit sale growth: 20% with exception of EVL® upon obtaining specific “visceral lipectomy”
modified 510(k) indication at end of 2018 (i.e. between 2018-2019, 30%) and upon obtaining insurance
reimbursement end of 2018 after short term efficacy studies, i.e. 2019-2020, 30%)
 Liposuctions or bariatric surgeries/year/surgeon: 24; Consumables/liposuction or EV L®: 1.
 Sales commission: 15% and Promotional Incentives (e.g. Cinch It™): 5%; Product Liability: 5%.
“Bottom Up” Conservative Projections FME 5/31/17 1,000‘s
16
2017 2018 2019 2020 2021
SALES $0 $3,017 $16,222 $24,181 $33,880
EBITDA ($1,942) ($270) $1,844 $3,042 $4,547
NET INCOME ($1,978,936) ($318,144) $1,796,303 $2,994,106 $3,042,199

18. Market Size Estimate of Potential Growth (“Top Down”)
 Estimated for treating only the obese patients with metabolic syndrome’s most severe
manifestation, diagnosed type 2 diabetes mellitus in the U.S.
 U.S. Diabetes Prevalence1
 In 2012, 29.1 million Americans, or 9.3% of the population, had diabetes.
 Approximately 1.25 million American children and adults have type 1 diabetes.
 Undiagnosed: 8.1 million were undiagnosed
 19.75M diagnosed, type 2 Diabetics in the U.S.
• Potential Market Size and Net Income
• $1,700 per single procedure consumable x 19.75M diagnosed type 2 U.S Diabetics x 31%
Net Profit = $10.41B Net Income
• 1% Market Penetration = $104M Net Income
• Market Growth1
• 1.4 million Americans are diagnosed with diabetes every year
• 1.4 Million new cases x $1,700 x 31% = $744M yearly target market growth
• Endocrinologists2 are recommending surgical intervention more frequently and earlier
• Surgery is more effective than diet and exercise for long term weight reduction.
1. American Diabetes Association:
http://www.diabetes.org/diabetes-basics/statistics/#sthash.FZsSxxWX.dpuf
2. Endocrine Society: http://www.news-medical.net/news/20140624/Weight-loss-surgery-more-effective-than-
diet-exercise.aspx
17

19. Investment Highlights
Large &
Growing
Market
 Persistence Market Research estimates the global bariatric surgery device
(bands, staples, clips, balloons, etc.) market size at $1.4B in 2014 with an
expected CAGR of 9.6% to reach $2.5B by 2020.
 McKinsey Global Institute reported world wide expenditures for Obesity-
Related Disease Diseases (diabetes, hypertension, sleep apnea, etc.)
reached $2T in 2014.
Strong
Management
Team
 Extensive experience and solid track record of successful execution.
 Sound vision and strategy for growth: management has extensive.
connections with key hospitals, industry doctors and opinion makers.
 Depth of professional, regulatory and licensing experience.
Sound Growth
Strategy
 Subscription revenue base model with add-on products or procedures.
 Large potential for branded centers opening: usage of extracted fat as
filler in various plastic procedures and cross selling opportunities.
 Worldwide expansion.
Viable Business
Model
 Proven concept and strong barriers to entry: third-generation device with
large IP Protection: 3 patents on method and device and numerous more
US pending.
 Short time to market: Estimated 12 months to create and test, large OEM
medical device company agreed to develop prototype and manufacture.
 Disruptive technology in both applications.
18

20. Contact
BioSculpture Technology, Inc.
Robert L. Cucin M.D., J.D., M.B.A.
CEO
Administrative Office
1701 South Flagler Drive
Suite 607
West Palm Beach, FL 33401
Tel (561) 651-7816
Tel: (212) 977-5400
Fax: (561) 651-7808
rlcucin2
ceo@biosculpturetechology.com
Research & Development Office
Okeechobee Plaza
1550-4 Latham Road
West Palm Beach, FL 33409
Tel: (212) 300-0060
Fax: (212) 400-4234
www.biosculpturetechnology.com www.evl.technology
19